ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 23, 2017 09:00 JST
Source:
Novotech Health Holdings Pte Ltd
Novotech signs Central Lab Services Agreement with Sonic Clinical Trials
SYDNEY, AU, Jun 23, 2017 - (ACN Newswire) - Asia Pacific specialist CRO Novotech announced today it has expanded its business offering to include central lab services through a preferred partnership agreement with Sonic Clinical Trials, an affiliate of international healthcare company, Sonic Healthcare.
Through this unique partnership, Novotech clients will be able to select from a wide menu of assays or biomarkers, access a trial-specific kit assembly service and use a single clinical trial-dedicated laboratory with a global reach, for priority processing of clinical trial samples.
Announcing the new partnership, Novotech CEO Dr. John Moller said, "Novotech has always focused on offering flexible and cost effective clinical trial solutions. Through our partnership with Sonic Clinical Trials, our clients will experience a seamless integration of laboratory services and clinical trial data management by Novotech. From the start to finish, our clients are supported by a team of dedicated project managers.
"Another key benefit to our clients is the fact that Sonic Clinical Trials is pre-audited and an approved Novotech vendor. This removes our clients' need to undertake their own central lab vendor assurance - providing a further savings in cost and clinical trial time."
Sonic Clinical Trials is a registered Research Service Provider (RSP) with AusIndustry, a division of the Australian Government's Department of Industry, Innovation and Science.
"Sonic Clinical Trials' RSP status assists our eligible international clients when accessing the Australian R&D Tax Incentive Scheme. Research from a recent Frost and Sullivan white paper revealed that eligible companies can conduct early stage clinical trials 60% more cheaply in Australia than the USA," explained Dr. Moller.
"Novotech's size and Asia Pacific focus allows our clients to enjoy a direct, hands-on approach to accessing some of the largest patient pools in the world, but we balance this with providing global gold-standard central laboratory services and data management platforms."
About Australian R&D Tax Incentive Scheme
Through the Australian R&D Tax Incentive Scheme, eligible companies may claim a 43.5% R&D tax refund on eligible R&D expenditure. For more information about this scheme, see the joint Novotech / Frost & Sullivan white paper, "Australia: The preferred destination for early phase clinical trials", Mar. 31, 2017.
http://novotech-cro.com/news-events
.
About Sonic Clinical Trials
Sonic Clinical Trials is a wholly owned subsidiary of Australian-owned Sonic Healthcare, one of the world's largest specialist medical diagnostics companies, employing more than 33,000 people in Australia, New Zealand, the United Kingdom, Germany, Switzerland, Belgium, Ireland and the USA. Sonic Clinical Trials is a registered Research Service Provider (RSP) with AusIndustry which allows it to assist international clients to register for the Australian R&D Tax Incentive Scheme. To learn more, please visit www.sonicclinicaltrials.com.au.
About Novotech
Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region, while it has worldwide reach through its network of strategic partners.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. For more information, please visit www.novotech-cro.com.
Media:
Digital Mantra Group
Susan Fitzpatrick-Napier
AU: +61 2 8218 2144 / USA: +1 650 798 5238
Email:
susan@dmgpr.com
Corporate:
Novotech
Justine Lamond
Marketing & Communications Manager
AU: +61 2 8569 1458
Email:
communications@novotech-cro.com
Source: Novotech Health Holdings Pte Ltd
Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 10:53 JST
All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating
Apr 18, 2024 09:22 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 17, 2024 16:17 JST
Honda Unveils Next-generation EV Series for China
Apr 17, 2024 12:15 JST
More Latest Release >>
Related Release
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
February 15 2023 09:00 JST
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
February 10 2023 19:00 JST
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
February 03 2023 13:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Novotech is Gold Sponsor at Biotech Showcase 2023
December 20 2022 11:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
December 06 2022 11:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
More Press release >>